HeartBeam Inc. (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, was supported by key stakeholders including ClearCardio(TM), company leadership, and institutional investors.
The funds will be used to support the commercialization of HeartBeam's FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of artificial intelligence capabilities, and general corporate purposes. The company's technology is designed to enable cable-free collection of ECG signals in 3D from three non-coplanar directions, synthesizing them into a 12-lead ECG. This platform is intended for portable devices that can be used wherever the patient is, allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility.
HeartBeam received FDA clearance for arrhythmia assessment in December 2024 and for the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to its technology. The successful closing of this offering marks a significant step toward bringing these innovations to market and potentially reshaping cardiac health management.
For more details on the offering, view the full press release here. Additional information on the company's cleared indications for use can be found on the HeartBeam website.
